Cancer :: Growth factor signals influence balance between normal growth and cancerous growth – USA

Too much of a signaling protein called insulin-like growth factor-I (IGF-I) may fan the flames of cancer, while too little of the protein may cause short stature, dementia and osteoporosis. New research investigates how the growth hormone/IGF system is affected by the important tumor suppressor gene p53. This interplay of two signaling pathways reinforces questions about the long-term risks of prescribing growth hormone, while suggesting a future new avenue for cancer therapy.

Leukemia :: Researchers identify cells that make relapse inevitable in acute lymphoblastic leukemia

Scientists in Australia have discovered that in acute lymphoblastic leukemia (ALL) there are “good” and “evil” clones of the same type of ALL cell. The “evil” cells are clones that have a pre-existing resistance to drugs used for treating ALL, and their presence in a patient means that person will inevitably relapse after chemotherapy, according to research presented at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

Child Care :: Violent spell rivals worst times for Palestinian children

UNICEF is distressed by the extraordinary violence in northern Gaza. Since 1 November, we estimate that 68 Palestinians have been killed, including 14 children. The deaths during the last seven days, including the children killed in today’s shelling, add to the steady deadly toll on Palestinian children since the Intifada broke out in 2000, with 113 children killed so far this year. This is more than double the total figure for 2005.

Osteosarcoma :: IDM Pharma’s Mepact, mifamurtide – Junovan in the Treatment of Osteosarcoma

IDM Pharma (NASDAQ:IDMI) announced today that the company has submitted a Marketing Authorization Application (MAA) in eCTD format (electronic common technical document) to the European Medicines Agency (EMEA) for Mepact (mifamurtide for injection), requesting approval for its use in the treatment of patients with newly diagnosed resectable high-grade osteosarcoma following surgical resection in combination with post-operative multi-agent chemotherapy. This announcement follows the October 25, 2006 submission of a New Drug Application (NDA) for Junovan (mifamurtide for injection) to the Food and Drug Administration (FDA) in the United States.

Leukemia :: The Edd Griffith trust fund

The family of a 17-year-old boy who died at the Royal Free of leukaemia has set up a trust fund in his memory. Edward Griffith, better known as Edd, died at the end of the summer following a two year battle against the disease.

ADHD :: Study Evaluates Two Medications for ADHD

University of Illinois at Chicago researchers are comparing two drugs commonly used to treat attention deficit hyperactivity disorder to determine if genetic factors predict which children will respond to either or both drugs.

Health Care :: Allied Health Professions Week Highlights Workforce Shortage Crisis

The first baby boomers are turning 60 this year. Some question whether there will be enough health care professionals to take care of them. An aging society and increased cases of chronic conditions like diabetes and obesity are straining an already fragile health care workforce. Now, the University of Missouri-Columbia is looking at ways to write a prescription for one of the major ailments facing today?s society, according to Richard Oliver, dean of the MU School of Health Professions. MU recently spearheaded the creation of FuturePoint Summit, a national coalition of academic and business leaders in the health care field, to find solutions for the allied health workforce shortage.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack